Skip to main content

Advertisement

SpringerLink
Log in

Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology

  • Educational Series – Red Series
  • New Trends in Clinical Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The last decade has seen substantial progress in the diagnostic and therapeutic approach to lung cancer, thus meaning that its prognosis has improved. The Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology have therefore produced a national consensus statement to make recommendations for radiological diagnosis and assessment of treatment response in patients with lung cancer. This expert group recommends multi-detector computed tomography as the technique of choice for investigating this disease. The radiology report should include a full assessment by the TNM staging system. Lastly, when the patient is on immunotherapy, response evaluation should employ not only response evaluation criteria in solid tumours, but also immune-related response criteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC; 2012.

  2. Fraioli F, Anzidei M, Zaccagna F, Mennini ML, Serra G, Gori B, et al. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology. 2011;259:574–82.

    Article  PubMed  Google Scholar 

  3. Yuan X, Zhang J, Quan C, Cao J, Ao G, Tian Y, et al. Differentiation of malignant and benign pulmonary nodules with first-pass dual-input perfusion CT. Eur Radiol. 2013;23:2469–74.

    Article  PubMed  Google Scholar 

  4. Baumueller S, Winklehner A, Karlo C, Goetti R, Flohr T, Russi EW, et al. Low-dose CT of the lung: potential value of iterative reconstructions. Eur Radiol. 2012;22:2597–606.

    Article  PubMed  Google Scholar 

  5. Lu GM, Zhao Y, Zhang LJ, Schoepf UJ. Dual-energy CT of the lung. AJR Am J Roentgenol. 2012;199:S40–53.

    Article  PubMed  Google Scholar 

  6. Calzado Cantera A, Hernández-Girón I, Salvadó Artells M, Rodríguez González R. Estado actual y tendencia en el desarrollo tecnológico para la reducción de dosis en los equipos de tomografía computarizada. Radiología. 2013;55:9–16.

    Article  PubMed  Google Scholar 

  7. Directiva 2013/59 Euratom del consejo de 5 de diciembre de 2013 por la que se establecen las normas de seguridad básicas para la protección contra los peligros derivados de la exposición a radiaciones ionizantes y se derogan las directivas 89/618 Euratom, 97/43 Euratom, 96/29 Euratom, 97/43 Euratom y 2003/122 Euratom. Art 60/61. Diario oficial de la unión europea 17 de Enero 2014.

  8. Hurwitz LM, Reiman RE, Yoshizumi TT, Goodman PC, Toncheva G, Nguyen G, et al. Radiation dose from contemporary cardiothoracic multidetector CT protocols with an anthropomorphic female phantom: implications for cancer induction. Radiology. 2007;245:742–50.

    Article  PubMed  Google Scholar 

  9. Yilmaz MH, Albayram S, Yasar D, Ozer H, Adaletli I, Selcuk D, et al. Female breast radiation exposure during thorax multidetector computed tomography and the effectiveness of bismuth breast shield to reduce breast radiation dose. J Comput Assist Tomogr. 2007;31:138–42.

    Article  PubMed  Google Scholar 

  10. Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112:333–40.

    Article  PubMed  Google Scholar 

  11. Pahade JK, Litmanovich D, Pedrosa I, Romero J, Bankier AA, Boiselle PM. Quality initiatives: imaging pregnant patients with suspected pulmonary embolism: what the radiologist needs to know. Radiographics. 2009;29:639–54.

    Article  PubMed  Google Scholar 

  12. Dewachter P, Laroche D, Mouton-Faivre C, Bloch-Morot E, Cercueil JP, Metge L, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol. 2011;77:495–501.

    Article  PubMed  Google Scholar 

  13. Liccardi G, Lobefalo G, Di Florio E, Di Iorio C, Occhiochiuso L, Romano L, et al. Strategies for the prevention of asthmatic, anaphylactic and anaphylactoid reactions during the administration of anesthetics and/or contrast media. J Investig Allergol Clin Immunol. 2008;18:1–11.

    CAS  PubMed  Google Scholar 

  14. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol. 2008;190:187–90.

    Article  PubMed  Google Scholar 

  15. European Society of Urogenital Radiology (ESUR) guidelines on contrast media. 2014 http://www.esur.org/esur-guidelines/. Accessed May 2014.

  16. Alexopoulos E, Spargias K, Kyrzopoulos S, Manginas A, Pavlides G, Voudris V, et al. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. Am J Med Sci. 2010;339:25–30.

    Article  PubMed  Google Scholar 

  17. Jost G, Pietsch H, Lengsfeld P, Hutter J, Sieber MA. The impact of the viscosity and osmolality of iodine contrast agents on renal elimination. Invest Radiol. 2010;45:255–61.

    Article  PubMed  Google Scholar 

  18. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–71.

    Article  PubMed  Google Scholar 

  19. Nair A, Klusmann MJ, Jogeesvaran KH, Grubnic S, Green SJ, Vlahos I. Revisions to the TNM staging of non-small cell lung cancer: rationale, clinicoradiologic implications, and persistent limitations. Radiographics. 2011;31:215–38.

    Article  PubMed  Google Scholar 

  20. Herth F, Ernst A, Schulz M, Becker H. Endobronchial ultrasound reliably differentiates between airway infiltration and compression by tumor. Chest. 2003;123:458–62.

    Article  PubMed  Google Scholar 

  21. Fibla JJ, Cassivi SD, Brunelli A, Decker PA, Allen MS, Darling GE, et al. Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set. Lung Cancer. 2012;78:259–62.

    Article  PubMed  Google Scholar 

  22. Kawase A, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Visceral pleural invasion classification in non-small cell lung cancer. J Thorac Oncol. 2010;5:1784–8.

    Article  PubMed  Google Scholar 

  23. Glazer HS, Duncan-Meyer J, Aronberg DJ, Moran JF, Levitt RG, Sagel SS. Pleural and chest wall invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1985;157:191–4.

    Article  CAS  PubMed  Google Scholar 

  24. Bandi V, Lunn W, Ernst A, Eberhardt R, Hoffmann H, Herth FJ. Ultrasound vs. CT in detecting chest wall invasion by tumor: a prospective study. Chest. 2008;133:881–6.

    Article  PubMed  Google Scholar 

  25. Barlesi F, Balleyguier C, Besse B, Bonodeau F, Brenac F, Corneloup O, et al. Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Ann Oncol. 2010;21:1682–6.

    Article  CAS  PubMed  Google Scholar 

  26. Glazer HS, Kaiser LR, Anderson DJ, Molina PL, Emami B, Roper CL, et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1989;173:37–42.

    Article  CAS  PubMed  Google Scholar 

  27. Herman SJ, Winton TL, Weisbrod GL, Towers MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology. 1994;190:841–6.

    Article  CAS  PubMed  Google Scholar 

  28. Reck M, Barlesi F, Crino L, Henschke CI, Isla D, Stiebeler S, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol. 2012;23:1111–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg. 2006;29:26–9.

    Article  PubMed  Google Scholar 

  30. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178S–201S.

    Article  PubMed  Google Scholar 

  31. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.

    Article  PubMed  Google Scholar 

  32. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax. 2009;64:139–43.

    Article  CAS  PubMed  Google Scholar 

  33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  34. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.

    Article  CAS  PubMed  Google Scholar 

  35. Cervera Deval J. [RECIST and the radiologist]. Radiologia. 2014;56:193–205.

  36. Chalian H, Tore HG, Horowitz JM, Salem R, Miller FH, Yaghmai V. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics. 2011;31:2093–105.

    Article  PubMed  Google Scholar 

  37. Lee HY, Lee KS, Ahn MJ, Hwang HS, Lee JW, Park K, et al. New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer. 2011;73:63–9.

    Article  PubMed  Google Scholar 

  38. Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, et al. New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010;195:W221–8.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010;195:281–9.

    Article  PubMed  Google Scholar 

  40. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 2010;20:1456–67.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Yaghmai V, Miller FH, Rezai P, Benson AB 3rd, Salem R. Response to treatment series: part 2, tumor response assessment–using new and conventional criteria. AJR Am J Roentgenol. 2011;197:18–27.

    Article  PubMed  Google Scholar 

  42. Larici AR, del Ciello A, Maggi F, Santoro SI, Meduri B, Valentini V, et al. Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer. Radiographics. 2011;31:771–89.

    Article  PubMed  Google Scholar 

  43. Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol. 2011;79:147–54.

    Article  PubMed  Google Scholar 

  44. Rodrigues G, Lock M, D’Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose—volume histogram parameters in lung cancer–a systematic review. Radiother Oncol. 2004;71:127–38.

    Article  PubMed  Google Scholar 

  45. Decker RH, Wilson LD. Advances in radiotherapy for lung cancer. Semin Respir Crit Care Med. 2008;29:285–90.

    Article  PubMed  Google Scholar 

  46. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35:309–21.

    Article  CAS  PubMed  Google Scholar 

  47. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22:4442–5.

    Article  PubMed  Google Scholar 

  48. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol. 2009;27:404–10.

    Article  CAS  PubMed  Google Scholar 

  49. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.

    Article  PubMed  Google Scholar 

  50. Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K, et al. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J Radiol. 2010;11:618–26.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Miles KA, Lee TY, Goh V, Klotz E, Cuenod C, Bisdas S, et al. Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol. 2012;22:1430–41.

    Article  CAS  PubMed  Google Scholar 

  52. Li Y, Yang ZG, Chen TW, Chen HJ, Sun JY, Lu YR. Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer. 2008;61:44–53.

    Article  PubMed  Google Scholar 

  53. Ma SH, Le HB, Jia BH, Wang ZX, Xiao ZW, Cheng XL, et al. Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer. 2008;8:186.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Spira D, Neumeister H, Spira SM, Hetzel J, Spengler W, von Weyhern CH, et al. Assessment of tumor vascularity in lung cancer using volume perfusion CT (VPCT) with histopathologic comparison: a further step toward an individualized tumor characterization. J Comput Assist Tomogr. 2013;37:15–21.

    Article  PubMed  Google Scholar 

  55. Tacelli N, Remy-Jardin M, Copin MC, Scherpereel A, Mensier E, Jaillard S, et al. Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology. 2010;257:863–71.

    Article  PubMed  Google Scholar 

  56. Fraioli F, Anzidei M, Serra G, Liberali S, Fiorelli A, Zaccagna F, et al. Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects. Br J Radiol. 2013;86:20120174.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Lind JS, Meijerink MR, Dingemans AM, van Kuijk C, Ollers MC, de Ruysscher D, et al. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol. 2010;20:2890–8.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Tacelli N, Santangelo T, Scherpereel A, Duhamel A, Deken V, Klotz E, et al. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol. 2013;23:2127–36.

    Article  PubMed  Google Scholar 

  59. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Non-small cell lung cancer. Version 3. 2014. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed May 2014.

  60. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii56–64.

Download references

Acknowledgments

The authors acknowledge the editorial assistance provided by Ana Martín from HealthCo (Madrid, Spain) in the preparation of this manuscript.

Conflict of interest

SEOM and SERAM wish to thank AstraZeneca, Novartis, and Roche for the financial support of this project through no restriction grants. The authors declare that during the writing and revision of this consensus, they did not know the name of the pharmaceutical companies supporting this project. Thus, the financial support has no influence in the content of this article.

Author information

Authors and Affiliations

  1. Oncology Department, La Paz University Hospital, Paseo de la Castellana, 261, 28046, Madrid, Spain

    J. de Castro

  2. Oncology Department, Carlos Haya Hospital, Málaga, Spain

    M. Cobo

  3. Oncology Department, Lozano Blesa Clinic Hospital, Zaragoza, Spain

    D. Isla

  4. Oncology Department, San Carlos Clinic Hospital, Madrid, Spain

    J. Puente

  5. Oncology Department, Clinic Hospital, Barcelona, Spain

    N. Reguart

  6. Radiology Department, San Carlos Clinic Hospital, Madrid, Spain

    B. Cabeza & J. Ferreirós

  7. Radiology Department, del Mar Hospital, Barcelona, Spain

    A. Gayete

  8. Radiology Department, CDI, Clinic Hospital, Barcelona, Spain

    M. Sánchez

  9. Radiology Department, La Paz University Hospital, Madrid, Spain

    M. I. Torres

Authors
  1. J. de Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Cobo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Isla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Puente
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Reguart
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Cabeza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Gayete
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. I. Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. Ferreirós
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. de Castro.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Castro, J., Cobo, M., Isla, D. et al. Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. Clin Transl Oncol 17, 11–23 (2015). https://doi.org/10.1007/s12094-014-1231-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1231-5

Keywords

Search

Navigation